Krystle Vermes

The National Advertising Review Board is recommending that Bayer Healthcare LLC stop claiming that "nothing works faster than Claritin-D."

Rhino 7 3000 and Rhino 7 3000 Platinum Capsules, which are marketed as dietary supplements for sexual enhancement, have been voluntarily recalled for undeclared ingredients.

Once-daily combination would be the first all-oral, pan-genotypic single tablet for treatment of HCV.

The FDA is reviewing Gilead Sciences' new drug application (NDA) for a fixed dose combination of sofosbuvir (Solvadi) and velpatasvir to treat genotype 1-6 hepatitis C virus infection.

Mylan has launched a generic version of Spectrum Pharmaceuticals' levoleucovorin calcium injections.

The FDA has determined that entacapone, a drug used in the treatment of Parkinson's disease, does not increase patients' risk of heart attacks, stroke, or other cardiovascular events.

Kayexalate must be further evaluated to see if it binds to other oral medications that may reduce potency.

The FDA is requiring AbbVie to add new warnings about serious liver injury to the labels of its hepatitis C treatments, Viekira Pak and Technivie.

Drugs carry risk for contamination and infection.

The FDA is requiring Concordia Pharmaceuticals to conduct studies on its hyperkalemia treatment, sodium polystyrene sulfonate (Kayexalate), to see if it binds to other medications administered by mouth, which would decrease potency.

Downing Labs, a retail pharmacy based in Texas, has issued a voluntary recall of all lots of sterile products.

Allergan has launched an OTC artificial tear product for dry eyes.

Pfizer asked to provide additional safety analyses for proposed indication.

The FDA has rejected Pfizer's supplemental new drug application to expand the use of tofacitinib citrate.

Testing may optimize medication efficacy, adherence, and patient care.

DNA4Life has launched a new test for patients who want to know how their bodies will respond to some of the most commonly prescribed therapeutic medications.

Medline Industries is voluntarily recalling 1 lot of acetaminophen tablets.

Drug helps improve glycemic control of type 2 diabetes not adequately controlled on a regimen of empagliflozin or metformin alone.

Drug reduces the risk of acute urinary retention and the risk for BPH-related surgery.

Synjardy, a type 2 diabetes treatment, is now available by prescription in US pharmacies.

Recall affects products that were compounded prior to September 1, 2015.

A generic version of Avodart, used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate, has been launched by Teva Pharmaceutical Industries Ltd.

Supplemental New Drug Application includes the treatment of acute bacterial skin and skin-structure infections.

The FDA has approved a single-use lens delivery system for patients undergoing cataract surgery.

The FDA is considering expanding the use of Allergen's skin infection drug dalbavancin (Dalvance).

Expansion addresses patients co-infected with HIV, patients with advanced cirrhosis, and patients with post-liver transplant HCV recurrence.

Combination reduces the risk of hospitalization for worsening symptoms and improves exercise ability.

The FDA is considering expanding the use for a drug currently indicated as a chronic hepatitis C (HCV) treatment.

Device identifies diabetes risk, in addition to diagnosing and monitoring patients.

The FDA has approved a new treatment combination of Gilead's ambrisentan (Letairis) with tadalafil to treat pulmonary arterial hypertension.